Which of the following is not a feature of AML?
A. Retinoic acid is used in treatmentB. 15/17 translocation may be seen
C. CD 15/34 both seen in same cell
D. Associated with disseminated intravascular coagulation (DIC)
Ans. C. (CD 15/34 both seen in
same cell)
Explanation
Tretinoin (45 mg/kg per day orally until remission is documented) plus concurrent anthracycline chemotherapy appears to be among the safest and most effective treatments for APL (acute promyelocytic leukemia). Unlike patients with other types of AML, patients with this subtype benefit from maintenance therapy with either tretinoin or chemotherapy. AML FAB M3 is now designated acutepromyelocytic leukemia (APL), based on the presence of either the t(l5; 17) (q22q12) cytogenetic rearrangement or the PML/RARu product of the translocation. Similar examples exist with a variety of other balance translocations and inversions, including the t(8;2 1), t(9; 11), t (6;9) and mv (16).
Tretinoin (45 mg/kg per day orally until remission is documented) plus concurrent anthracycline chemotherapy appears to be among the safest and most effective treatments for APL (acute promyelocytic leukemia). Unlike patients with other types of AML, patients with this subtype benefit from maintenance therapy with either tretinoin or chemotherapy. AML FAB M3 is now designated acutepromyelocytic leukemia (APL), based on the presence of either the t(l5; 17) (q22q12) cytogenetic rearrangement or the PML/RARu product of the translocation. Similar examples exist with a variety of other balance translocations and inversions, including the t(8;2 1), t(9; 11), t (6;9) and mv (16).
Various
physicalfindings are as follows:
• Ecchymosis and oozing from IV
sites (DIC, possible acute promyelocytic leukemia)
• Fever and tachycardia (signs
of infection)
• Papilledema, retinal
infiltrates, cranial nerve abnormalities (CNS leukemia) poor dentition, dental
abscesses
• Gum hypertrophy (leukemic
infiltration, most common in monocytic leukemia)
• Skin infiltration or nodules
(leukemia infiltration MC in monocytic leukemia
• Lymphadenopathy,
splenomegaly, hepatomegaly
• Back
pain, lower extremity weakness (spinal granulocytic sarcoma, most likely in
t(8;21) patients 